The present invention relates to a novel pharmaceutical formulation comprising phenytoin sodiuma high amount of magnesium stearate and a low level of a hydrophilic polymer such as a methocel and a method of preparing the same by blending.

A monomeric adhesive composition includes a stabilized polymerizable monomer, such as a 1,1-disubstituted monomer, including a cyanoacrylate, and a wound healing agent, wherein the wound healing agent is 5,5-disubstitutedhydantoin, including phenytoin

A monomeric adhesive composition includes a stabilized polymerizable monomer such as a 11-disubstituted monomer including a cyanoacrylate and a wound healing agent wherein the wound healing agent is 55-disubstitutedhydantoin including phenytoin; and a method for making said composition.

The present invention relates to a novel pharmaceutical formulation comprising phenytoin sodium a high amount of magnesium stearate and a low level of a hydrophilic polymer such as a methocel and a method of preparing the same by blending.

The present invention relates to a novel pharmaceutical formulation comprising phenytoin sodium a high amount of magnesium stearate and a low level of a hydrophilic polymer such as a methocel and a method of preparing the same by blending.

The present invention relates to a novel pharmaceutical formulation comprising phenytoin sodium, a high amount of magnesium stearate, and a low level of a hydrophilic polymer such as a methocel, and a method of preparing the same by blending.

The invention provides a method of treating acute demyelinating optic neuritis in a patient suffering therefrom, which method comprises administering a compound to the patient, wherein the compound is phenytoin or an analog or prodrug thereof. The compound acts as a neuroprotectant by partial blocking of voltage-gated sodium channels in axonal other cell membranes thereby reducing the entry of sodium into the respective cell in vivo. The treatment is particularly concerned with preserving vision...